Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Overview of attention for article published in Lancet Oncology, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog

twitter: 96 X users
guideline: 1 clinical guideline source

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

No Improvement With Trastuzumab in HER2-Overexpressing Esophageal Cancer

Cancer Therapy Advisor, 03 Feb 2022

Adding trastuzumab to chemoradiotherapy followed by surgery did not improve outcomes for patients with HER2-overexpressing…

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

The Medical News, 23 Jan 2022

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did…

Trastuzumab with chemoradiation and surgery does not improve outcomes for esophageal cancer patients

MedicalXpress, 21 Jan 2022

Credit: Pixabay/CC0 Public Domain The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab…

Trastuzumab with chemoradiation and surgery does not improve outcomes for esophageal cancer patients, trial highlights future research opportunities

EurekAlert!, 21 Jan 2022

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.